Logo
x

Search

Subscribe Now

larotrectinib

Bayer Reports Submission of MAA to the MHLW for Larotrectinib to Treat Solid Tumors with TRK Fusion

Bayer Reports Submission of MAA to the MHLW for Larotrectinib to Treat Solid Tumors with TRK Fusion

  • May 22, 2020
Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology

Bayer Exercises its Exclusive WW Option to License Vitrakvi & BAY 2731954 with Change-In-Control Clause from Loxo Oncology

  • February 18, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.